Infection prevention and control measures during the COVID-19 pandemic and airborne tuberculosis transmission during primary care visits in South Africa.

Publication date: Jul 01, 2025

Tuberculosis (TB) transmission in crowded health care settings poses considerable risks in high-burden regions. We assessed how COVID-19 pandemic-related infection prevention and control (IPC) measures might impact TB transmission in a South African primary care clinic. In 2019 (prepandemic) and 2021 (pandemic), we collected clinical data, patient tracking data (person-time and spatial density), indoor CO levels, and concentrations of Mycobacterium tuberculosis (Mtb) DNA in bio-aerosol samples. We estimated the risk of Mtb transmission during a 1-hour visit based on ventilation rate and duration of exposure. During the pandemic, clinics were less crowded, with lower mean person-time per day (209 vs 258 hours; P < 0. 001). TB prevalence among patients also declined (1. 1% vs 4. 7%; P = 0. 052). Environmental indicators suggested improved air quality, with lower CO₂ levels (555 vs 856 parts-per-million; P < 0. 001) and higher ventilation rates (15. 8 vs 6. 3 air changes per hour; P < 0. 001). These changes corresponded with a reduction in modeled Mtb transmission risk (0. 04% vs 1. 36%; P = 0. 046). Airborne Mtb DNA was detected in both periods. Pandemic-related IPC measures to control COVID-19 transmission were rigorously implemented and likely reduced transmission of airborne respiratory infections, supporting their continued implementation in healthcare settings postpandemic.

Concepts Keywords
Africa Adult
Environmental Air Microbiology
Improved Airborne transmission
Postpandemic Carbon dioxide
Tuberculosis COVID-19
Female
Genomic DNA
Healthcare facilities
Humans
Infection Control
Male
Middle Aged
Mycobacterium tuberculosis
Pandemics
Primary Health Care
SARS-CoV-2
South Africa
Tuberculosis
Tuberculosis
Young Adult

Semantics

Type Source Name
disease MESH Infection
disease MESH COVID-19 pandemic
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Medical air
disease IDO quality
disease MESH respiratory infections
drug DRUGBANK Carbon dioxide

Original Article

(Visited 1 times, 1 visits today)